 "Coronavirus, vaccine, covid, drugs, clinical trials")
Serum Institute of India, that has completed phase-3 trial with over 1,600 volunteers in India, is expected to submit the final set of data before the subject expert committee in the next 10 days or so, according to people in the know.
If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca’s vaccine candidate, can come in by the first week of January.
Last week, the panel, advising the country’s drug regulator on Covid-19 vaccines, sought additional data from Serum. The firm has completed phase-3 trial in India on November 25. The immunogenicity (whether the vaccine produces the desired immune response)
